Oruka Therapeutics, Inc. Common Stock ORKA
Analyst Ratings
- Consensus
- Buy — 9 Buy · 0 Hold · 0 Sell (9 analysts)
- Avg. Price Target
- $128.78 (+32.9% upside)
Key Stats
- Today's Range
- $94.75 – $97.60
- 50-Day Range
- $70.50 – $109.52
- 52-Week Range
- $15.00 – $115.52
- Volume
- 634K shs
- Average Volume
- 986K shs
- Market Cap
- $6.40 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.61%
- Days to Cover
- 12.78
About Oruka Therapeutics, Inc. Common Stock
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
Related Stocks
Compare head-to-head: ORKA vs LLY·ORKA vs JNJ·ORKA vs ABBV·ORKA vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.